MRVI · Insider Trading
Maravai LifeSciences Holdings, Inc. Class A Common Stock
Every open-market purchase and sale reported by MRVI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-09 | Bernd Brust | Chief Executive Officer | F | −29,250 | −$217.33K |
| 2026-10-01 | Rajesh Asarpota | Chief Financial Officer | F | −5,465 | −$41.81K |
| 2026-09-09 | Bernd Brust | Chief Executive Officer | F | −29,250 | −$214.11K |
| 2026-09-01 | Rajesh Asarpota | Chief Financial Officer | F | −5,465 | −$41.97K |
| 2026-08-11 | Bernd Brust | Chief Executive Officer | F | −29,250 | −$182.23K |
| 2026-08-03 | Rajesh Asarpota | Chief Financial Officer | F | −5,465 | −$36.01K |
| 2026-07-10 | Bernd Brust | Chief Executive Officer | F | −29,250 | −$173.16K |
| 2026-07-01 | Rajesh Asarpota | Chief Financial Officer | F | −65,584 | −$419.08K |
| 2026-06-10 | Kurt Oreshack | General Counsel | Sell | −50,000 | −$254.00K |
| 2026-06-10 | Gregory T Lucier | Director | G | — | — |
| 2026-06-10 | Bernd Brust | Chief Executive Officer | F | −351,001 | −$1.76M |
| 2026-05-28 | Constantine S Mihas | Director | A | +46,293 | — |
| 2026-05-28 | R Andrew Eckert | Director | A | +46,293 | — |
| 2026-05-28 | Luke Joseph Marker | Director | A | +46,293 | — |
| 2026-05-28 | Gregory T Lucier | Director | A | +46,293 | +$202.76K |
| 2026-05-28 | Sean Laurence Cunningham | Director | A | +46,293 | — |
| 2026-05-28 | John A DeFord | Director | A | +46,293 | — |
| 2026-05-28 | Gregory T Lucier | Director | A | +46,293 | — |
| 2026-05-28 | Susannah Gray | Director | A | +46,293 | — |
| 2026-05-22 | Christine Dolan | See Remarks | A | +5,006 | +$8.96K |
| 2026-05-22 | Kurt Oreshack | General Counsel | A | +776 | +$2.20K |
| 2026-03-17 | Christine Dolan | See Remarks | F | −28,661 | −$88.28K |
| 2026-03-17 | Kurt Oreshack | General Counsel | F | −39,976 | −$123.13K |
| 2026-01-20 | Christine Dolan | See Remarks | F | −28,934 | −$106.77K |
| 2026-01-20 | Kurt Oreshack | General Counsel | F | −31,902 | −$117.72K |
| 2025-12-09 | Gregory T Lucier | Director | Buy | +100,000 | +$368.54K |
| 2025-11-18 | Christine Dolan | See Remarks | A | +4,300 | +$7.70K |
| 2025-11-17 | Bernd Brust | Chief Executive Officer | Buy | +216,212 | +$702.69K |
| 2025-11-13 | Bernd Brust | Chief Executive Officer | Buy | +250,559 | +$809.01K |
| 2025-07-16 | Peter Michael Leddy | See Remarks | F | −5,154 | −$13.35K |
| 2025-07-11 | Gregory T Lucier | Director | G | — | — |
| 2025-06-30 | Rajesh Asarpota | Chief Financial Officer | A | +500,000 | — |
| 2025-06-18 | Susannah Gray | Director | A | +89,139 | +$192.54K |
| 2025-06-18 | John A DeFord | Director | A | +89,139 | +$192.54K |
| 2025-06-18 | R Andrew Eckert | Director | A | +231,481 | +$500.00K |
| 2025-06-18 | Murali Prahalad | Director | A | +89,139 | +$192.54K |
| 2025-06-18 | Gregory T Lucier | Director | A | +89,139 | +$192.54K |
| 2025-06-18 | Luke Joseph Marker | Director | A | +89,139 | +$192.54K |
| 2025-06-18 | Jessica Hopfield | Director | A | +89,139 | +$192.54K |
| 2025-06-18 | Constantine S Mihas | Director | A | +89,139 | +$192.54K |
| 2025-06-18 | Sean Laurence Cunningham | Director | A | +89,139 | +$192.54K |
| 2025-06-18 | Benjamin James Daverman | Director | A | +89,139 | +$192.54K |
| 2025-06-10 | Bernd Brust | Chief Executive Officer | A | +2,000,000 | — |
| 2025-05-28 | Kevin Herde | Chief Financial Officer | A | +876 | +$1.46K |
| 2025-05-28 | Christine Dolan | See Remarks | A | +2,381 | +$3.98K |
| 2025-03-19 | Kurt Oreshack | General Counsel | A | +295,858 | — |
| 2025-03-19 | Kevin Herde | Chief Financial Officer | F | −8,648 | −$22.83K |
| 2025-03-19 | Peter Michael Leddy | See Remarks | A | +394,478 | — |
| 2025-03-19 | William E. Martin III | Chief Executive Officer | A | +986,194 | — |
| 2025-03-19 | Rebecca Buzzeo | See Remarks | F | −4,314 | −$11.39K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bernd Brust | Chief Executive Officer | 1,998,770 | $14.13M |
| William E. Martin III | Chief Executive Officer | 1,814,643 | $12.83M |
| Peter Michael Leddy | See Remarks | 727,177 | $5.14M |
| Kevin Herde | Chief Financial Officer | 674,636 | $4.77M |
| Rebecca Buzzeo | See Remarks | 606,791 | $4.29M |
| Christine Dolan | See Remarks | 425,318 | $3.01M |
| Rajesh Asarpota | Chief Financial Officer | 418,021 | $2.96M |
| R Andrew Eckert | Director | 412,183 | $2.91M |
| Andrew Burch | See Remarks | 369,183 | $2.61M |
| Kurt Oreshack | General Counsel | 360,767 | $2.55M |
| Gregory T Lucier | Director | 311,200 | $2.20M |
| Carl Hull | See Remarks | 302,072 | $2.14M |
| Susannah Gray | Director | 216,200 | $1.53M |
| John A DeFord | Director | 205,478 | $1.45M |
| Jessica Hopfield | Director | 199,907 | $1.41M |
| Constantine S Mihas | Director | 184,348 | $1.30M |
| Sean Laurence Cunningham | Director | 184,348 | $1.30M |
| Luke Joseph Marker | Director | 184,348 | $1.30M |
| Murali Prahalad | Director | 154,607 | $1.09M |
| Benjamin James Daverman | Director | 138,055 | $976.05K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MRVI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.